However, the majority of non-Hodgkin lymphomas (NHLs), including DLBCL, fall between currently ill-defined “immunosuppressed” and “cold” TME categories (16, 17), which likely contributes to suboptimal responses to anti–PD-1 or chimeric antigen receptor (CAR) T cell immunotherapies (18–20). Here, PDCD1 is linked to diffuse large B-cell lymphoma.